CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: CYP20A1 (ImmuneEditome ID:57404)

1. Gene summary of enriched editing regions for CYP20A1

check button Gene summary
Gene informationGene symbol

CYP20A1

Gene ID

57404

GeneSynonymsCYP-M
GeneCytomap

2q33.2

GeneTypeprotein-coding
GeneDescriptioncytochrome P450 20A1|cytochrome P450 monooxygenase|cytochrome P450, family 20, subfamily A, polypeptide 1
GeneModificationdate20230329
UniprotIDQ6UW02;F2Z3K6;F8WBE2;C9J8K7;E9PHG5
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr2:203297273-203305523:+ENST00000613925.3ENSG00000119004.13CYP20A1splicingAluSp,AluSx1,AluSc8,(TTACACT)n,AluSz,AluSg,AluSq2,AluSx3,AluSz6,AluJo,AluSx,AluJr,AluSc,L1M,(AT)n,AluJbchr2:203297273-203305523:+.alignment


Top

2. Tumor-specific enriched editing regions for CYP20A1


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr2:203297273-203305523:+BRCAEER5.5746e-17image
ENSG00000119004.13,CYP20A1BRCAEAG5.9840e-17image
chr2:203297273-203305523:+KIRPEER4.8328e-02image
ENSG00000119004.13,CYP20A1KIRPEAG4.8572e-02image
chr2:203297273-203305523:+LIHCEER3.0039e-02image
ENSG00000119004.13,CYP20A1LIHCEAG3.0039e-02image
chr2:203297273-203305523:+LUSCEER9.1222e-13image
ENSG00000119004.13,CYP20A1LUSCEAG9.1236e-13image
chr2:203297273-203305523:+PRADEER8.6592e-03image
ENSG00000119004.13,CYP20A1PRADEAG8.4832e-03image
chr2:203297273-203305523:+THCAEER1.1063e-22image
ENSG00000119004.13,CYP20A1THCAEAG1.1518e-22image
chr2:203297273-203305523:+UCECEER5.8024e-09image
ENSG00000119004.13,CYP20A1UCECEAG5.8048e-09image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr2:203297273-203305523:+BLCAPathEER7.1117e-038.7313e-040.1692image
ENSG00000119004.13,CYP20A1BLCAPathEAG7.1117e-038.7313e-040.1692image
chr2:203297273-203305523:+ESCACliEER7.0765e-041.0732e-02-0.3477image
ENSG00000119004.13,CYP20A1ESCACliEAG6.6326e-041.0377e-02-0.3492image
ENSG00000119004.13,CYP20A1KIRPCliEAG4.7708e-037.7518e-040.2388image
chr2:203297273-203305523:+KIRPCliEER4.7555e-037.7152e-040.2389image
chr2:203297273-203305523:+OVCliEER3.8298e-029.2832e-030.1347image
ENSG00000119004.13,CYP20A1OVCliEAG3.8145e-029.2664e-030.1348image
chr2:203297273-203305523:+THCAPathEER3.8660e-072.6344e-070.2271image
ENSG00000119004.13,CYP20A1THCAPathEAG3.9566e-072.8059e-070.2266image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr2:203297273-203305523:+OVEER4.9427e-031.9828e-031.6245e+02image
ENSG00000119004.13,CYP20A1OVEAG4.9427e-031.9844e-031.6286e+02image

Top

3. Enriched editing regions and immune related genes for CYP20A1


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr2:203297273-203305523:+LGGEERENSG00000119004,CYP20A1-0.40123.1270e-189.1000e-25-0.4274imageNADAR;BCCIP;CSTF2T;DDX54;DGCR8;DHX9;DKC1;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FUS;GTF2F1;HNRNPC;HNRNPL;IGF2BP2;KHSRP;MSI1;NOP56;NOP58;PCBP2;RBFOX2;RBM47;SMNDC1;SRSF9;TARDBP;U2AF1;U2AF2;UPF1NAMast_cells_activatedGSVA_HALLMARK_KRAS_SIGNALING_DN
chr2:203297273-203305523:+COADEERENSG00000181222,POLR2A0.19133.4136e-027.8346e-140.4408imageNBCCIP;CSTF2T;DDX54;DGCR8;DHX9;DKC1;ELAVL1;FAM120A;FBL;FUS;GTF2F1;HNRNPC;HNRNPL;IGF2BP2;KHSRP;MSI1;NOP56;NOP58;RBFOX2;SAFB2;SLBP;SMNDC1;SRSF9;TARDBP;U2AF1;U2AF2;UPF1NADendritic_cells_activatedGSVA_HALLMARK_APICAL_SURFACE
chr2:203297273-203305523:+COADEERENSG00000220205,VAMP20.19213.4507e-021.1072e-120.4218imageNADAR;BCCIP;CSTF2T;DDX54;DGCR8;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FUS;GTF2F1;HNRNPC;HNRNPL;IGF2BP2;KHSRP;NOP56;NOP58;PCBP2;RBFOX2;RBM47;SAFB2;SMNDC1;SRSF9;TARDBP;U2AF1;U2AF2;UPF1NADendritic_cells_activatedGSVA_HALLMARK_MYC_TARGETS_V2
chr2:203297273-203305523:+COADEERENSG00000151176,PLBD20.18743.9276e-021.7832e-170.4942imageNADAR;BCCIP;CSTF2T;DDX54;DGCR8;DHX9;DKC1;ELAVL1;FAM120A;FBL;FUS;GTF2F1;HNRNPC;HNRNPL;IGF2BP2;KHSRP;MSI1;NOP56;NOP58;PCBP2;RBFOX2;RBM47;SAFB2;SMNDC1;SRSF9;TARDBP;U2AF1;U2AF2;UPF1NADendritic_cells_activatedGSVA_HALLMARK_DNA_REPAIR
chr2:203297273-203305523:+GBMEERENSG00000207547,MIR25-0.53481.0797e-089.5458e-09-0.4271imageNNNAT_cells_follicular_helperGSVA_HALLMARK_APOPTOSIS
chr2:203297273-203305523:+GBMEERENSG00000232611,RP11-1114A5.4-0.53011.5499e-084.0157e-10-0.4612imageNBCCIP;CSTF2T;DDX54;DGCR8;DHX9;DKC1;ELAVL1;EWSR1;FAM120A;FBL;FUS;GTF2F1;HNRNPC;IGF2BP2;KHSRP;NOP56;NOP58;RBFOX2;SAFB2;SMNDC1;SRSF9;TARDBP;U2AF1;U2AF2;UPF1NAT_cells_follicular_helperGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr2:203297273-203305523:+GBMEERENSG00000235313,HM13-IT1-0.51803.6759e-086.7461e-09-0.4310imageNBCCIP;CSTF2T;DHX9;ELAVL1;FBL;FUS;IGF2BP2;NOP56;NOP58;RBFOX2;SAFB2;SMNDC1;SRSF9;U2AF2NAMacrophages_M0GSVA_HALLMARK_ADIPOGENESIS
chr2:203297273-203305523:+GBMEERENSG00000124193,SRSF6-0.51027.3110e-081.9872e-08-0.4186imageNADAR;BCCIP;CSTF2T;DDX54;DGCR8;DHX9;DKC1;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FUS;GTF2F1;HNRNPC;HNRNPL;IGF2BP2;KHDRBS3;KHSRP;MSI1;NOP56;NOP58;PCBP2;RBFOX2;RBM47;SAFB2;SLBP;SMNDC1;SRSF9;TARDBP;U2AF1;U2AF2;UPF1NAMonocytesGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr2:203297273-203305523:+GBMEERENSG00000119004,CYP20A1-0.50989.0304e-081.1091e-09-0.4507imageNADAR;BCCIP;CSTF2T;DDX54;DGCR8;DHX9;DKC1;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FUS;GTF2F1;HNRNPC;HNRNPL;IGF2BP2;KHSRP;MSI1;NOP56;NOP58;PCBP2;RBFOX2;RBM47;SMNDC1;SRSF9;TARDBP;U2AF1;U2AF2;UPF1NAMonocytesGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr2:203297273-203305523:+GBMEERENSG00000196653,ZNF502-0.50581.1784e-071.0828e-10-0.4743imageNDGCR8;ELAVL1;EWSR1;FBL;FUS;HNRNPC;IGF2BP2;KHSRP;NOP56;NOP58;RBFOX2;RBM47;SAFB2;TARDBP;U2AF2NAT_cells_gamma_deltaGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY

More results



Top

4. Enriched editing regions and immune related splicing for CYP20A1


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr2:203297273-203305523:+
COADEERMEXENSG00000164687.6chr881280362:81280674:81283365:81283538:81283914:81283974:81284513:812847770.26616.5267e-031.8611e-110.4002imageNCSTF2T;ELAVL1;FAM120A;FBL;FUS;IGF2BP2;KHSRP;NOP58;PCBP2;RBFOX2;SRSF9;TARDBP;U2AF1;U2AF2;UPF1NAT_cells_follicular_helperGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000119004.13,CYP20A1
COADEAGMEXENSG00000164687.6chr881280362:81280674:81283365:81283538:81283914:81283974:81284513:812847770.26408.5890e-031.7368e-110.4007imageNBUD13;CELF2;CSTF2T;DDX3X;EIF4A3;ELAVL1;FAM120A;FBL;FUS;HNRNPA1;HNRNPA2B1;HNRNPK;IGF2BP1;IGF2BP2;IGF2BP3;KHSRP;LIN28A;MBNL2;NONO;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;SF3A3;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;U2AF1;U2AF2;UPF1;YTHDC1;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000119004.13,CYP20A1
COADEAGMEXENSG00000013306.11chr1744321057:44321231:44321433:44321558:44322807:44322852:44323283:44323343-0.22344.6764e-021.3063e-17-0.4968imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAEosinophilsGSVA_HALLMARK_DNA_REPAIR
chr2:203297273-203305523:+
COADEERMEXENSG00000013306.11chr1744321057:44321231:44321433:44321558:44322807:44322852:44323283:44323343-0.22663.6772e-021.2776e-17-0.4969imageNBCCIP;CSTF2T;DDX54;DGCR8;DKC1;ELAVL1;FAM120A;FBL;FUS;GTF2F1;HNRNPC;HNRNPL;IGF2BP2;KHSRP;MSI1;NOP56;NOP58;PCBP2;RBFOX2;RBM47;SAFB2;SLBP;SMNDC1;SRSF9;TARDBP;U2AF1;U2AF2;UPF1NAEosinophilsGSVA_HALLMARK_DNA_REPAIR
chr2:203297273-203305523:+
GBMEERIRENSG00000155229.16chr1097460694:97461007:97461827:974618960.28638.7671e-031.5403e-060.4145imageNADAR;BCCIP;CSTF2T;DDX54;DGCR8;DHX9;DKC1;ELAVL1;ELAVL3;FAM120A;FBL;FUS;GTF2F1;HNRNPC;HNRNPL;IGF2BP2;KHDRBS3;KHSRP;MSI1;NOP56;NOP58;PCBP2;RBFOX2;SAFB2;SMNDC1;SRSF9;TARDBP;U2AF1;U2AF2;UPF1NAT_cells_gamma_deltaGSVA_HALLMARK_HEME_METABOLISM
chr2:203297273-203305523:+
GBMEERIRENSG00000007516.9chr161346718:1346955:1347297:1347358-0.31622.2597e-034.7602e-06-0.4008imageNADAR;CSTF2T;DDX54;DGCR8;ELAVL1;FAM120A;FBL;FUS;GTF2F1;IGF2BP2;NOP56;NOP58;PCBP2;RBFOX2;SMNDC1;SRSF9;TARDBP;U2AF1;U2AF2;UPF1NAT_cells_CD8GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000119004.13,CYP20A1
GBMEAGIRENSG00000099904.11chr2220139719:20139892:20140114:20140217-0.43037.9168e-053.3301e-08-0.4233imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;WTAP;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
ENSG00000119004.13,CYP20A1
GBMEAGIRENSG00000102967.7chr1672021123:72021311:72022361:72022475-0.37766.7085e-045.2966e-08-0.4264imageNADAR;AIFM1;AUH;BCCIP;BUD13;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184DHODHT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
ENSG00000119004.13,CYP20A1
GBMEAGIRENSG00000125901.5chr203046613:3046900:3047734:3048254-0.32321.4212e-031.0077e-07-0.4630imageNAIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;LIN28A;LIN28B;MOV10;MSI2;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr2:203297273-203305523:+
GBMEERIRENSG00000139998.10chr1464949836:64950414:64951073:64951151-0.38071.2014e-049.7726e-09-0.4801imageNADAR;BCCIP;CSTF2T;DDX54;DGCR8;DHX9;DKC1;ELAVL1;ELAVL3;FAM120A;FBL;FUS;GTF2F1;HNRNPC;HNRNPL;IGF2BP2;NOP56;NOP58;PCBP2;RBFOX2;SMNDC1;SRSF9;TARDBP;U2AF1;U2AF2;UPF1NAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS

More results



Top

5. Enriched editing regions and immune infiltration for CYP20A1


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr2:203297273-203305523:+ACCEERNK_cells_resting1.8750e-02-0.2640image
ENSG00000119004.13,CYP20A1ACCEAGNK_cells_resting1.8750e-02-0.2640image
chr2:203297273-203305523:+BLCAEEREosinophils2.8978e-040.1842image
ENSG00000119004.13,CYP20A1BLCAEAGEosinophils2.8978e-040.1842image
chr2:203297273-203305523:+BRCAEERB_cells_naive1.0324e-04-0.1180image
ENSG00000119004.13,CYP20A1BRCAEAGB_cells_naive9.9040e-05-0.1183image
chr2:203297273-203305523:+COADEERDendritic_cells_activated1.0257e-030.2021image
ENSG00000119004.13,CYP20A1COADEAGDendritic_cells_activated1.0241e-030.2021image
chr2:203297273-203305523:+DLBCEERT_cells_follicular_helper1.8384e-02-0.3427image
ENSG00000119004.13,CYP20A1DLBCEAGT_cells_follicular_helper1.8384e-02-0.3427image
chr2:203297273-203305523:+ESCAEERT_cells_regulatory_(Tregs)3.5662e-08-0.4176image
ENSG00000119004.13,CYP20A1ESCAEAGT_cells_regulatory_(Tregs)3.5670e-08-0.4176image
chr2:203297273-203305523:+HNSCEERT_cells_regulatory_(Tregs)1.9676e-04-0.1879image
ENSG00000119004.13,CYP20A1HNSCEAGT_cells_regulatory_(Tregs)1.9970e-04-0.1877image
chr2:203297273-203305523:+KIRCEERMacrophages_M04.0310e-020.1052image
ENSG00000119004.13,CYP20A1KIRCEAGMacrophages_M03.7202e-020.1069image
chr2:203297273-203305523:+KIRPEERNK_cells_activated3.7233e-03-0.1722image
ENSG00000119004.13,CYP20A1KIRPEAGNK_cells_activated3.7803e-03-0.1719image
chr2:203297273-203305523:+LAMLEERNK_cells_activated1.2048e-02-0.2073image
ENSG00000119004.13,CYP20A1LAMLEAGNK_cells_activated1.2356e-02-0.2066image
chr2:203297273-203305523:+LGGEEREosinophils1.1144e-050.1903image
ENSG00000119004.13,CYP20A1LGGEAGEosinophils1.1156e-050.1903image
chr2:203297273-203305523:+LIHCEERMast_cells_resting1.3704e-020.1305image
ENSG00000119004.13,CYP20A1LIHCEAGMast_cells_resting1.3704e-020.1305image
chr2:203297273-203305523:+LUADEERT_cells_CD4_memory_activated8.5311e-030.1176image
ENSG00000119004.13,CYP20A1LUADEAGT_cells_CD4_memory_activated8.5311e-030.1176image
chr2:203297273-203305523:+MESOEERMast_cells_resting3.9438e-02-0.2279image
ENSG00000119004.13,CYP20A1MESOEAGMast_cells_resting3.9438e-02-0.2279image
chr2:203297273-203305523:+OVEERT_cells_CD87.6744e-050.2305image
ENSG00000119004.13,CYP20A1OVEAGT_cells_CD87.2715e-050.2312image
chr2:203297273-203305523:+PAADEERT_cells_CD4_memory_resting2.8890e-020.1652image
ENSG00000119004.13,CYP20A1PAADEAGT_cells_CD4_memory_resting2.8888e-020.1652image
chr2:203297273-203305523:+PCPGEERDendritic_cells_activated1.2204e-020.1865image
ENSG00000119004.13,CYP20A1PCPGEAGDendritic_cells_activated1.2204e-020.1865image
chr2:203297273-203305523:+PRADEERPlasma_cells3.8017e-06-0.2058image
ENSG00000119004.13,CYP20A1PRADEAGPlasma_cells3.6906e-06-0.2061image
chr2:203297273-203305523:+READEERMast_cells_activated2.6131e-020.2306image
ENSG00000119004.13,CYP20A1READEAGMast_cells_activated2.6131e-020.2306image
chr2:203297273-203305523:+SKCMEERMast_cells_resting6.9603e-03-0.1297image
ENSG00000119004.13,CYP20A1SKCMEAGMast_cells_resting6.9603e-03-0.1297image
chr2:203297273-203305523:+STADEERT_cells_CD4_memory_activated3.4281e-080.2838image
ENSG00000119004.13,CYP20A1STADEAGT_cells_CD4_memory_activated3.3451e-080.2841image
chr2:203297273-203305523:+TGCTEERT_cells_regulatory_(Tregs)5.6305e-04-0.2731image
ENSG00000119004.13,CYP20A1TGCTEAGT_cells_regulatory_(Tregs)5.6305e-04-0.2731image
chr2:203297273-203305523:+THCAEERT_cells_regulatory_(Tregs)6.3500e-060.1996image
ENSG00000119004.13,CYP20A1THCAEAGT_cells_regulatory_(Tregs)7.4262e-060.1981image
chr2:203297273-203305523:+THYMEERMacrophages_M17.8286e-090.5006image
ENSG00000119004.13,CYP20A1THYMEAGMacrophages_M17.8286e-090.5006image
chr2:203297273-203305523:+UCSEERT_cells_CD4_memory_activated9.1119e-030.3455image
ENSG00000119004.13,CYP20A1UCSEAGT_cells_CD4_memory_activated9.1424e-030.3453image


Top

6. Enriched editing regions and immune gene sets for CYP20A1


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr2:203297273-203305523:+BRCAEER8.4411e-04image1.1748e-020.0768image
ENSG00000119004.13,CYP20A1BRCAEAG8.5103e-04image1.2184e-020.0764image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr2:203297273-203305523:+BLCAEER8.2561e-050.19981.9786e-070.26204.3025e-040.17902.1009e-040.1883image
ENSG00000119004.13,CYP20A1BLCAEAG8.2561e-050.19981.9786e-070.26204.3025e-040.17902.1009e-040.1883image
chr2:203297273-203305523:+BRCAEER3.9280e-100.18921.0823e-070.16107.9468e-070.14985.9837e-090.1761image
ENSG00000119004.13,CYP20A1BRCAEAG4.6397e-100.18841.1731e-070.16069.1395e-070.14897.0114e-090.1753image
chr2:203297273-203305523:+ESCAEER3.4387e-110.49194.6940e-020.15681.3714e-110.50051.5869e-070.3990image
ENSG00000119004.13,CYP20A1ESCAEAG3.3606e-110.49214.6276e-020.15731.3456e-110.50071.5800e-070.3990image
chr2:203297273-203305523:+LUADEER1.7311e-040.16732.4025e-040.16373.0270e-030.13254.1005e-050.1825image
ENSG00000119004.13,CYP20A1LUADEAG1.7311e-040.16732.4025e-040.16373.0270e-030.13254.1005e-050.1825image
chr2:203297273-203305523:+SARCEER8.2385e-030.16581.1225e-030.20372.5826e-020.14012.1226e-030.1923image
ENSG00000119004.13,CYP20A1SARCEAG8.4196e-030.16531.1744e-030.20292.5889e-020.14011.9593e-030.1938image
chr2:203297273-203305523:+STADEER1.0021e-180.44011.1092e-070.27356.7008e-130.36449.6996e-170.4164image
ENSG00000119004.13,CYP20A1STADEAG1.1091e-180.43961.1712e-070.27307.4359e-130.36371.0565e-160.4159image
chr2:203297273-203305523:+THYMEER8.6420e-03-0.24071.5841e-02-0.22172.4643e-050.37789.8942e-080.4668image
ENSG00000119004.13,CYP20A1THYMEAG8.6420e-03-0.24071.5841e-02-0.22172.4643e-050.37789.8942e-080.4668image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000119004.13,CYP20A1ACCGSVA_HALLMARK_HEME_METABOLISMEAG1.2218e-030.3574image
chr2:203297273-203305523:+ACCGSVA_HALLMARK_HEME_METABOLISMEER1.2218e-030.3574image
ENSG00000119004.13,CYP20A1BLCAGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG8.7899e-110.3235image
chr2:203297273-203305523:+BLCAGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER8.7899e-110.3235image
chr2:203297273-203305523:+BRCAGSVA_HALLMARK_GLYCOLYSISEER5.7560e-250.3072image
ENSG00000119004.13,CYP20A1BRCAGSVA_HALLMARK_GLYCOLYSISEAG8.5027e-250.3061image
chr2:203297273-203305523:+CESCGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER6.2227e-110.3717image
ENSG00000119004.13,CYP20A1CESCGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG6.2227e-110.3717image
chr2:203297273-203305523:+CHOLGSVA_HALLMARK_PROTEIN_SECRETIONEER7.2496e-040.5443image
ENSG00000119004.13,CYP20A1CHOLGSVA_HALLMARK_PROTEIN_SECRETIONEAG7.2496e-040.5443image
chr2:203297273-203305523:+COADGSVA_HALLMARK_SPERMATOGENESISEER2.4747e-03-0.1866image
ENSG00000119004.13,CYP20A1COADGSVA_HALLMARK_SPERMATOGENESISEAG2.2952e-03-0.1879image
ENSG00000119004.13,CYP20A1DLBCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG4.5335e-02-0.2934image
chr2:203297273-203305523:+DLBCGSVA_HALLMARK_KRAS_SIGNALING_DNEER4.5335e-02-0.2934image
ENSG00000119004.13,CYP20A1ESCAGSVA_HALLMARK_HYPOXIAEAG1.5800e-070.3990image
chr2:203297273-203305523:+ESCAGSVA_HALLMARK_HYPOXIAEER1.5869e-070.3990image
ENSG00000119004.13,CYP20A1GBMGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG6.6558e-060.3416image
chr2:203297273-203305523:+GBMGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER6.6558e-060.3416image
ENSG00000119004.13,CYP20A1HNSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG1.6291e-060.2406image
chr2:203297273-203305523:+HNSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER2.2310e-060.2375image
chr2:203297273-203305523:+KICHGSVA_HALLMARK_KRAS_SIGNALING_DNEER3.5495e-02-0.2613image
ENSG00000119004.13,CYP20A1KICHGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.5495e-02-0.2613image
chr2:203297273-203305523:+KIRCGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER1.8032e-130.3657image
ENSG00000119004.13,CYP20A1KIRCGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG9.6772e-140.3696image
chr2:203297273-203305523:+KIRPGSVA_HALLMARK_ADIPOGENESISEER2.4702e-120.4013image
ENSG00000119004.13,CYP20A1KIRPGSVA_HALLMARK_ADIPOGENESISEAG2.6692e-120.4007image
ENSG00000119004.13,CYP20A1LAMLGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG9.1522e-040.2715image
chr2:203297273-203305523:+LAMLGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER1.0423e-030.2687image
chr2:203297273-203305523:+LGGGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER1.6993e-110.2879image
ENSG00000119004.13,CYP20A1LGGGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG1.7145e-110.2878image
ENSG00000119004.13,CYP20A1LIHCGSVA_HALLMARK_PEROXISOMEEAG3.7159e-090.3060image
chr2:203297273-203305523:+LIHCGSVA_HALLMARK_PEROXISOMEEER3.7159e-090.3060image
ENSG00000119004.13,CYP20A1LUADGSVA_HALLMARK_MTORC1_SIGNALINGEAG2.8476e-090.2619image
chr2:203297273-203305523:+LUADGSVA_HALLMARK_MTORC1_SIGNALINGEER2.8476e-090.2619image
ENSG00000119004.13,CYP20A1LUSCGSVA_HALLMARK_GLYCOLYSISEAG1.1014e-060.2239image
chr2:203297273-203305523:+LUSCGSVA_HALLMARK_GLYCOLYSISEER1.1015e-060.2239image
chr2:203297273-203305523:+MESOGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER3.2416e-030.3214image
ENSG00000119004.13,CYP20A1MESOGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG3.2416e-030.3214image
chr2:203297273-203305523:+OVGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.3151e-160.4609image
ENSG00000119004.13,CYP20A1OVGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.3174e-160.4609image
chr2:203297273-203305523:+PAADGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER2.1417e-040.2763image
ENSG00000119004.13,CYP20A1PAADGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG2.1410e-040.2763image
ENSG00000119004.13,CYP20A1PCPGGSVA_HALLMARK_PROTEIN_SECRETIONEAG6.6493e-070.3605image
chr2:203297273-203305523:+PCPGGSVA_HALLMARK_PROTEIN_SECRETIONEER6.6493e-070.3605image
ENSG00000119004.13,CYP20A1PRADGSVA_HALLMARK_E2F_TARGETSEAG9.5763e-050.1743image
chr2:203297273-203305523:+PRADGSVA_HALLMARK_E2F_TARGETSEER9.0775e-050.1748image
ENSG00000119004.13,CYP20A1READGSVA_HALLMARK_HEME_METABOLISMEAG9.1061e-030.2691image
chr2:203297273-203305523:+READGSVA_HALLMARK_HEME_METABOLISMEER9.1061e-030.2691image
ENSG00000119004.13,CYP20A1SARCGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.0425e-050.2732image
chr2:203297273-203305523:+SARCGSVA_HALLMARK_PROTEIN_SECRETIONEER1.1150e-050.2723image
chr2:203297273-203305523:+SKCMGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER8.0815e-030.1273image
ENSG00000119004.13,CYP20A1SKCMGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG8.0815e-030.1273image
ENSG00000119004.13,CYP20A1STADGSVA_HALLMARK_UV_RESPONSE_UPEAG7.7012e-280.5301image
chr2:203297273-203305523:+STADGSVA_HALLMARK_UV_RESPONSE_UPEER6.8062e-280.5306image
chr2:203297273-203305523:+TGCTGSVA_HALLMARK_PROTEIN_SECRETIONEER2.3628e-070.3996image
ENSG00000119004.13,CYP20A1TGCTGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.3628e-070.3996image
chr2:203297273-203305523:+THCAGSVA_HALLMARK_GLYCOLYSISEER8.2961e-170.3593image
ENSG00000119004.13,CYP20A1THCAGSVA_HALLMARK_GLYCOLYSISEAG8.0626e-170.3595image
ENSG00000119004.13,CYP20A1THYMGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.6682e-140.6320image
chr2:203297273-203305523:+THYMGSVA_HALLMARK_PROTEIN_SECRETIONEER1.6682e-140.6320image
chr2:203297273-203305523:+UCECGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER2.2513e-030.2301image
ENSG00000119004.13,CYP20A1UCECGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG2.2746e-030.2299image
chr2:203297273-203305523:+UCSGSVA_HALLMARK_MTORC1_SIGNALINGEER3.1838e-020.2872image
ENSG00000119004.13,CYP20A1UCSGSVA_HALLMARK_MTORC1_SIGNALINGEAG3.1849e-020.2872image
chr2:203297273-203305523:+UVMGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER2.5601e-02-0.2812image
ENSG00000119004.13,CYP20A1UVMGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG2.5601e-02-0.2812image


Top

7. Enriched editing regions and drugs for CYP20A1


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000119004.13,CYP20A1ACCGDC.0449EAG3.4812e-040.3924image
chr2:203297273-203305523:+ACCGDC.0449EER3.4812e-040.3924image
chr2:203297273-203305523:+BLCAKIN001.135EER6.1858e-05-0.2032image
ENSG00000119004.13,CYP20A1BLCAKIN001.135EAG6.1858e-05-0.2032image
chr2:203297273-203305523:+BRCACCT007093EER6.9869e-050.1209image
ENSG00000119004.13,CYP20A1BRCACCT007093EAG8.3631e-050.1196image
chr2:203297273-203305523:+CESCFTI.277EER1.0800e-05-0.2552image
ENSG00000119004.13,CYP20A1CESCFTI.277EAG1.0800e-05-0.2552image
ENSG00000119004.13,CYP20A1CHOLEmbelinEAG7.6281e-03-0.4434image
chr2:203297273-203305523:+CHOLEmbelinEER7.6281e-03-0.4434image
ENSG00000119004.13,CYP20A1COADBX.795EAG8.7168e-04-0.2048image
chr2:203297273-203305523:+COADBX.795EER9.5365e-04-0.2033image
ENSG00000119004.13,CYP20A1DLBCCGP.082996EAG3.5097e-02-0.3082image
chr2:203297273-203305523:+DLBCCGP.082996EER3.5097e-02-0.3082image
ENSG00000119004.13,CYP20A1ESCADocetaxelEAG5.6489e-06-0.3491image
chr2:203297273-203305523:+ESCADocetaxelEER5.7603e-06-0.3488image
ENSG00000119004.13,CYP20A1GBMGNF.2EAG2.4859e-07-0.3876image
chr2:203297273-203305523:+GBMGNF.2EER2.4859e-07-0.3876image
ENSG00000119004.13,CYP20A1HNSCEHT.1864EAG2.8292e-050.2108image
chr2:203297273-203305523:+HNSCEHT.1864EER2.9326e-050.2104image
chr2:203297273-203305523:+KIRCAG.014699EER3.3267e-070.2582image
ENSG00000119004.13,CYP20A1KIRCAG.014699EAG2.4069e-070.2612image
chr2:203297273-203305523:+KIRPGW.441756EER6.7696e-10-0.3569image
ENSG00000119004.13,CYP20A1KIRPGW.441756EAG6.7704e-10-0.3569image
ENSG00000119004.13,CYP20A1LAMLCCT018159EAG1.0947e-02-0.2100image
chr2:203297273-203305523:+LAMLCCT018159EER1.2027e-02-0.2074image
chr2:203297273-203305523:+LGGGSK.650394EER4.7809e-140.3207image
ENSG00000119004.13,CYP20A1LGGGSK.650394EAG4.8665e-140.3206image
ENSG00000119004.13,CYP20A1LIHCIPA.3EAG7.9132e-080.2802image
chr2:203297273-203305523:+LIHCIPA.3EER7.9132e-080.2802image
chr2:203297273-203305523:+LUADGemcitabineEER1.8926e-04-0.1664image
ENSG00000119004.13,CYP20A1LUADGemcitabineEAG1.8926e-04-0.1664image
ENSG00000119004.13,CYP20A1LUSCBIRB.0796EAG7.2054e-040.1564image
chr2:203297273-203305523:+LUSCBIRB.0796EER7.2054e-040.1564image
chr2:203297273-203305523:+MESOBX.795EER1.9458e-03-0.3373image
ENSG00000119004.13,CYP20A1MESOBX.795EAG1.9458e-03-0.3373image
ENSG00000119004.13,CYP20A1OVAZ628EAG1.0029e-10-0.3685image
chr2:203297273-203305523:+OVAZ628EER8.6209e-11-0.3697image
chr2:203297273-203305523:+PAADCEP.701EER3.9368e-030.2207image
ENSG00000119004.13,CYP20A1PAADCEP.701EAG3.9387e-030.2207image
ENSG00000119004.13,CYP20A1PCPGLenalidomideEAG1.2679e-040.2818image
chr2:203297273-203305523:+PCPGLenalidomideEER1.2679e-040.2818image
ENSG00000119004.13,CYP20A1PRADCCT018159EAG1.3542e-040.1705image
chr2:203297273-203305523:+PRADCCT018159EER1.5083e-040.1694image
chr2:203297273-203305523:+READBAY.61.3606EER2.2867e-02-0.2358image
ENSG00000119004.13,CYP20A1READBAY.61.3606EAG2.2867e-02-0.2358image
ENSG00000119004.13,CYP20A1SARCImatinibEAG5.1518e-04-0.2168image
chr2:203297273-203305523:+SARCImatinibEER5.1706e-04-0.2167image
ENSG00000119004.13,CYP20A1SKCMLapatinibEAG8.2638e-050.1887image
chr2:203297273-203305523:+SKCMLapatinibEER8.2638e-050.1887image
chr2:203297273-203305523:+STADCCT007093EER1.1221e-070.2734image
ENSG00000119004.13,CYP20A1STADCCT007093EAG1.1575e-070.2731image
chr2:203297273-203305523:+TGCTEmbelinEER1.1234e-03-0.2584image
ENSG00000119004.13,CYP20A1TGCTEmbelinEAG1.1234e-03-0.2584image
chr2:203297273-203305523:+THCAIPA.3EER2.8607e-200.3950image
ENSG00000119004.13,CYP20A1THCAIPA.3EAG3.0350e-200.3948image
chr2:203297273-203305523:+THYMGW843682XEER2.7505e-150.6462image
ENSG00000119004.13,CYP20A1THYMGW843682XEAG2.7505e-150.6462image
chr2:203297273-203305523:+UCECEpothilone.BEER3.1183e-03-0.2229image
ENSG00000119004.13,CYP20A1UCECEpothilone.BEAG3.2876e-03-0.2217image
chr2:203297273-203305523:+UCSBMS.754807EER1.1474e-020.3355image
ENSG00000119004.13,CYP20A1UCSBMS.754807EAG1.1420e-020.3357image
chr2:203297273-203305523:+UVMBicalutamideEER1.5142e-03-0.3914image
ENSG00000119004.13,CYP20A1UVMBicalutamideEAG1.5142e-03-0.3914image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType